tiprankstipranks
Trending News
More News >
OneSource Specialty Pharma Limited (IN:ONESOURCE)
:ONESOURCE
India Market

OneSource Specialty Pharma Limited (ONESOURCE) Price & Analysis

Compare
0 Followers

ONESOURCE Stock Chart & Stats


ONESOURCE FAQ

What was OneSource Specialty Pharma Limited’s price range in the past 12 months?
OneSource Specialty Pharma Limited lowest stock price was ₹1163.05 and its highest was ₹2249.65 in the past 12 months.
    What is OneSource Specialty Pharma Limited’s market cap?
    OneSource Specialty Pharma Limited’s market cap is ₹228.75B.
      When is OneSource Specialty Pharma Limited’s upcoming earnings report date?
      OneSource Specialty Pharma Limited’s upcoming earnings report date is Feb 04, 2026 which is in 210 days.
        How were OneSource Specialty Pharma Limited’s earnings last quarter?
        OneSource Specialty Pharma Limited released its earnings results on May 05, 2025. The company reported ₹9 earnings per share for the quarter, the consensus estimate of ₹9 by ₹0.
          Is OneSource Specialty Pharma Limited overvalued?
          According to Wall Street analysts OneSource Specialty Pharma Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
            Does OneSource Specialty Pharma Limited pay dividends?
            OneSource Specialty Pharma Limited does not currently pay dividends.
            What is OneSource Specialty Pharma Limited’s EPS estimate?
            OneSource Specialty Pharma Limited’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does OneSource Specialty Pharma Limited have?
            OneSource Specialty Pharma Limited has 114,466,020 shares outstanding.
              What happened to OneSource Specialty Pharma Limited’s price movement after its last earnings report?
              OneSource Specialty Pharma Limited reported an EPS of ₹9 in its last earnings report, expectations of ₹9. Following the earnings report the stock price went up 4.115%.
                Which hedge fund is a major shareholder of OneSource Specialty Pharma Limited?
                Currently, no hedge funds are holding shares in IN:ONESOURCE

                ONESOURCE Stock 12 Month Forecast

                Average Price Target

                ₹2,000.00
                ▲(3.44%Upside)
                {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1235":"₹1,235","1618":"₹1,618","2001":"₹2,001","1426.5":"₹1,426.5","1809.5":"₹1,809.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2000,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">₹2.00K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2000,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">₹2.00K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2000,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">₹2.00K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1235,1426.5,1618,1809.5,2001],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1887.75,1896.3846153846155,1905.0192307692307,1913.6538461538462,1922.2884615384614,1930.923076923077,1939.5576923076924,1948.1923076923076,1956.826923076923,1965.4615384615386,1974.0961538461538,1982.7307692307693,1991.3653846153845,{"y":2000,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1887.75,1896.3846153846155,1905.0192307692307,1913.6538461538462,1922.2884615384614,1930.923076923077,1939.5576923076924,1948.1923076923076,1956.826923076923,1965.4615384615386,1974.0961538461538,1982.7307692307693,1991.3653846153845,{"y":2000,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1887.75,1896.3846153846155,1905.0192307692307,1913.6538461538462,1922.2884615384614,1930.923076923077,1939.5576923076924,1948.1923076923076,1956.826923076923,1965.4615384615386,1974.0961538461538,1982.7307692307693,1991.3653846153845,{"y":2000,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1617.45,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1617.45,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1617.45,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1617.45,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1617.45,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1617.45,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1617.45,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1573.65,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1236.85,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1629,"date":1743465600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1623.35,"date":1746057600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1623.35,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1887.75,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                Similar Stocks
                Company
                Price & Change
                Follow
                Balaxi Pharmaceuticals Limited
                Biofil Chemicals & Pharmaceuticals Ltd.
                Gkb Ophthalmics Limited
                Opto Circuits (India) Limited
                Vivimed Labs Limited
                Popular Stocks
                What am I Missing?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis